Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Public ClinicalTrials.gov record NCT06865105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
Study identification
- NCT ID
- NCT06865105
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2025 (Actual)
- Primary completion
- Aug 2029 (Estimated)
- Completion
- Aug 2029 (Estimated)
- Last update posted
- Nov 9, 2026
2025 – 2029
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Newport Huntington Medical Group /ID# 272764 | Huntington Beach | California | 92648-5994 | Recruiting |
| Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085 | Avon Park | Florida | 33825 | Recruiting |
| Clinical Research Of West Florida - Phase I Unit /ID# 273198 | Clearwater | Florida | 33765 | Recruiting |
| HMD Research LLC /ID# 273086 | Orlando | Florida | 32819 | Recruiting |
| West Broward Rheumatology Associates /ID# 272892 | Tamarac | Florida | 33321 | Recruiting |
| Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199 | Tampa | Florida | 33606 | Recruiting |
| Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469 | Chicago | Illinois | 60611 | Recruiting |
| Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879 | Skokie | Illinois | 60076 | Completed |
| Willow Rheumatology and Wellness /ID# 277354 | Willowbrook | Illinois | 60527 | Recruiting |
| Klein & Associates /ID# 272829 | Cumberland | Maryland | 21502 | Completed |
| Dartmouth-Hitchcock Medical Center /ID# 272702 | Lebanon | New Hampshire | 03756 | Recruiting |
| Paramount Medical Research and Consulting /ID# 272757 | Middleburg Heights | Ohio | 44130 | Recruiting |
| Altoona Center For Clinical Research /ID# 272593 | Duncansville | Pennsylvania | 16635 | Recruiting |
| Private Practice - Dr. Ramesh C. Gupta /ID# 272897 | Memphis | Tennessee | 38119 | Recruiting |
| Tekton Research - West Gate /ID# 272765 | Austin | Texas | 78745 | Recruiting |
| Arthritis and Rheumatology Research Institute - Frisco /ID# 277306 | Frisco | Texas | 75035 | Recruiting |
| Accurate Clinical Research - Houston /ID# 272754 | Houston | Texas | 77089-6142 | Recruiting |
| Tekton Research, LLC /ID# 272901 | San Antonio | Texas | 78251 | Recruiting |
| DM Clinical Research - Tomball /ID# 272760 | Tomball | Texas | 77375 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06865105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2026 · Synced Nov 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06865105 live on ClinicalTrials.gov.